Trust Signals
- All efficacy claims are tied to named trials with sample sizes and effect sizes.
- Side-effect rates come from the STEP 1 trial publication, not manufacturer marketing.
- We explicitly note where animal data does not translate to humans.
- Head-to-head tables include cases where the peptide loses or the evidence is weak.
- No affiliate links to peptide vendors. No sponsored content.
Key Takeaways
- GLP-1 peptides are 30-to-31-amino-acid incretin analogs that activate GLP-1R; native GLP-1 has a half-life of roughly 1 to 2 minutes, while semaglutide extends this to about 7 days through fatty-acid conjugation.
- Once-weekly semaglutide 2.4 mg produced a mean 14.9 percent body-weight reduction at 68 weeks in the STEP 1 RCT (n=1,961), the strongest human RCT weight data for any single GLP-1 agonist.
- Cardiovascular benefit is proven in high-risk populations: the SELECT trial (n=17,604) showed a 20 percent relative reduction in MACE with semaglutide 2.4 mg in non-diabetic obese adults.
- Weight regain after stopping is near-complete within one year without continued treatment, per the STEP 4 withdrawal trial.
- In the United States, GLP-1 receptor agonists require a prescription; unregulated research-grade peptides lack FDA-verified sterility and potency testing and carry meaningful safety risks.
What Are GLP-1 Peptides? (Direct Answer)
Table of Contents
- What is GLP-1 and where does it come from biologically?
- How do GLP-1 peptides work at the receptor level, with numbers?
- What does the evidence actually show? (Evidence Ledger)
- What do most pages get wrong about GLP-1 peptides?
- How do the different GLP-1 agents compare to each other?
- How do you get GLP-1 peptides legally and safely?
- What is the sourcing and purity reality for GLP-1 peptides?
- How do you read a GLP-1 product label or COA?
- What are the real risks and side effects?
- FAQ
- Sources
What Is GLP-1 and Where Does It Come From Biologically?
GLP-1 (glucagon-like peptide-1) is a 30-amino-acid peptide (GLP-1 7-36 amide, the biologically active form) cleaved from the proglucagon gene product in intestinal L-cells, primarily in the ileum and colon. A smaller amount is produced in alpha cells of the pancreas and in neurons of the nucleus tractus solitarius in the brainstem.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →L-cells release GLP-1 within minutes of nutrient ingestion, particularly in response to carbohydrates and fats. The hormone acts locally via the portal vein and systemically via the circulation. Its primary physiological roles are to augment glucose-stimulated insulin secretion from beta cells, suppress glucagon from alpha cells, and signal satiety to the brain.
The native peptide is a poor drug because the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves the first two N-terminal amino acids within roughly 1 to 2 minutes of entering circulation, inactivating it. This is the central engineering problem that all pharmaceutical GLP-1 peptides solve in different ways.
How Do GLP-1 Peptides Work at the Receptor Level, With Numbers?
The GLP-1 receptor (GLP-1R) is a class B G-protein-coupled receptor coupled primarily to Gs. Agonist binding activates adenylyl cyclase, raising intracellular cyclic AMP. In pancreatic beta cells, elevated cAMP potentiates voltage-gated calcium channel opening and insulin granule exocytosis, but only when glucose is already elevated above a threshold (roughly 5 mmol/L), which is why GLP-1 agonists have low hypoglycemia risk as monotherapy.
GLP-1R is also expressed in the hypothalamus, vagal afferents, stomach, intestine, heart, kidneys, and bone. Hypothalamic signaling, particularly in the arcuate nucleus (reducing neuropeptide Y / AgRP neurons) and in the nucleus tractus solitarius, is thought to drive the appetite suppression and weight-loss effect.
Half-life engineering across agents:
| Agent | Modification | Half-life | Route |
|---|---|---|---|
| Native GLP-1 | None | ~1 to 2 minutes | Endogenous |
| Exenatide (Byetta) | Heloderma-derived, DPP-4 resistant | ~2.4 hours | Subcutaneous twice daily |
| Liraglutide (Victoza) | C16 fatty acid albumin binding | ~13 hours | Subcutaneous once daily |
| Semaglutide (Ozempic/Wegovy) | C18 fatty diacid, 2 x Aib substitutions | ~7 days | Subcutaneous once weekly |
| Oral semaglutide (Rybelsus) | Same as above plus SNAC absorption enhancer | ~7 days | Oral once daily, ~1% bioavailability |
| Tirzepatide (Mounjaro/Zepbound) | Dual GIP/GLP-1 agonist, C18 fatty diacid | ~5 days | Subcutaneous once weekly |
Caveat: half-life data is from prescribing information and regulatory submissions. A longer half-life does not automatically mean greater efficacy; receptor occupancy, downstream signaling bias, and tissue distribution all matter.
What Does the Evidence Actually Show? (Evidence Ledger)
| Claimed Benefit | Best Evidence Type | Key Trial / Source | Effect Direction | Confidence |
|---|---|---|---|---|
| Weight loss (obesity, non-diabetic) | Large human RCT | STEP 1 (semaglutide 2.4 mg, n=1,961) | ~14.9% body weight reduction vs. 2.4% placebo at 68 weeks | High |
| Glycemic control (type 2 diabetes) | Multiple large RCTs | SUSTAIN program, PIONEER program | Consistent HbA1c reduction ~1.0 to 1.8 percentage points | High |
| Cardiovascular event reduction (T2D high-risk) | Large RCT (CVOT) | LEADER (liraglutide, n=9,340); SUSTAIN-6 (semaglutide, n=3,297) | Significant MACE reduction (HR ~0.87 and 0.74 respectively) | High |
| Cardiovascular event reduction (non-diabetic obese) | Large RCT | SELECT (semaglutide 2.4 mg, n=17,604) | 20% relative MACE reduction | High |
| Reduction in alcohol/food cravings (addiction signal) | Small RCTs, observational | Emerging; multiple small studies 2023 to 2025 | Directionally positive, effect size variable | Low to Moderate |
| Fatty liver (MASH/NAFLD) improvement | Phase 3 RCT | ESSENCE trial (semaglutide, NEJM 2024) | Significant histological improvement vs. placebo | Moderate to High |
| Kidney protection (CKD) | Large RCT | FLOW trial (semaglutide, n=3,533) | 24% reduction in composite kidney outcome | High |
| Anti-inflammatory / neurological benefit | Animal and small human data | Preclinical models; small Parkinson's pilot trials | Directionally positive; mechanism unclear | Very Low to Low |
| Muscle preservation during weight loss | Limited human data | DEXA substudies of STEP trials | Lean mass loss occurs proportional to total loss; not fully protective | Low to Moderate |
What Do Most Pages Get Wrong About GLP-1 Peptides?
This is the section most sites skip.
1. Native GLP-1 and GLP-1 receptor agonists are treated as interchangeable. They are not. Native GLP-1 is gone within 2 minutes. When a vendor sells a "GLP-1 peptide" for injection, the relevant question is which specific analog it is, at what purity, and at what dose. "GLP-1 peptide" is a class, not a product.
2. Oral bioavailability is presented as solved. Oral semaglutide (Rybelsus) reaches roughly 1 percent bioavailability even with the co-formulated SNAC absorption enhancer and strict fasting requirements (30 minutes before food, water only). Generic oral claims that "peptides can be taken by mouth" ignore that GLP-1 analogs are large, fragile molecules that are degraded by gastric acid and proteases. An oral GLP-1 product without an FDA-approved formulation is almost certainly not delivering meaningful systemic peptide.
3. Weight loss is presented as permanent. The STEP 4 withdrawal trial published in NEJM in 2021 showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within 52 weeks. This is a chronic-treatment drug for a chronic condition, not a course of therapy.
4. Compounded equals pharmaceutical. During the semaglutide shortage, compounding pharmacies could legally produce semaglutide under 503A or 503B rules. However, several FDA warning letters cited compounders using semaglutide sodium or semaglutide acetate salt forms rather than the base used in Ozempic/Wegovy. These salts have not been proven bioequivalent. The FDA explicitly stated these are not the same as approved products.
5. The thyroid tumor risk is consistently misrepresented in both directions. Rodent studies showed dose-dependent C-cell thyroid tumors at GLP-1R agonist exposures many times higher than clinical doses. The class carries a black-box warning. However, human registry data from the LEADER trial and epidemiological studies have not confirmed a human signal. The honest answer is: the rodent finding is real, human relevance is not established, and the warning is precautionary for patients with a personal or family history of medullary thyroid carcinoma or MEN2.
How Do the Different GLP-1 Agents Compare to Each Other and to Alternatives?
| Agent / Approach | Mean Weight Loss | MACE Evidence | Route / Frequency | Key Weakness |
|---|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | ~14.9% (STEP 1) | Yes (SELECT) | SQ once weekly | Cost, GI side effects, weight regain on stopping |
| Liraglutide 3 mg (Saxenda) | ~5 to 8% (SCALE trial) | Yes in T2D (LEADER), not studied for weight indication | SQ once daily | Daily injection, lower efficacy vs. semaglutide |
| Tirzepatide 15 mg (Zepbound) | ~20.9% (SURMOUNT-1) | Ongoing (SURPASS-CVOT) | SQ once weekly | MACE data not yet mature for weight indication |
| Orlistat 120 mg TID | ~3 to 5% | No large CVOT | Oral with meals | GI side effects (oily stools), low efficacy |
| Phentermine/topiramate ER | ~8 to 10% (CONQUER trial) | No CVOT | Oral once daily | Controlled substance, teratogenicity risk, cardiovascular concerns |
| Lifestyle intervention alone | ~2 to 5% sustained | Modest indirect evidence | Behavioral | Poor long-term adherence; least efficacy |
The peptide wins on efficacy for weight loss versus all approved oral agents and lifestyle. It loses on cost (Wegovy list price in the US exceeds $1,300/month without insurance), on the requirement for indefinite treatment, and on GI tolerability compared to oral medications for many patients.
How Do You Get GLP-1 Peptides Legally and Safely?
In the United States, all GLP-1 receptor agonists are Schedule-unscheduled but prescription-only drugs. The legal pathways are:
- Brand-name prescription through a licensed prescriber. A physician, NP, or PA evaluates you and, if appropriate, writes a prescription for Ozempic, Wegovy, Victoza, Saxenda, Mounjaro, or Zepbound. The prescription is filled at an accredited pharmacy. This is the only pathway that delivers an FDA-approved product.
- Compounded semaglutide through an FDA-registered compounding pharmacy (503A or 503B). This was legally available when branded products were on the FDA shortage list. The FDA removed semaglutide from the shortage list in early 2025, ending the legal basis for most compounders. Tirzepatide shortages have followed a similar pattern. Always confirm current shortage status at the FDA Drug Shortages Database before purchasing compounded versions.
- Telehealth prescribing platforms. Several licensed telehealth companies prescribe GLP-1 agonists after a clinical evaluation. The prescribers are licensed physicians or NPs. The medication is still dispensed through a licensed pharmacy. The clinical evaluation is real, even if brief.
What Is the Sourcing and Purity Reality for GLP-1 Peptides?
The research-peptide market sells semaglutide and other GLP-1 analogs with certificates of analysis (COAs) showing purities of 98 percent or higher, typically via HPLC. Here is what that number does and does not mean:
- HPLC purity is not sterility. A product can be 99% pure semaglutide by mass and still contain endotoxins (bacterial lipopolysaccharides) that cause septic reactions on injection. Endotoxin testing (LAL assay) is a separate requirement that pharmaceutical manufacturers must meet; research vendors typically do not.
- Peptide content can be measured as acetate salt. Lyophilized peptides often contain significant acetate (from synthesis and purification). If a COA reports peptide content without specifying the salt correction, the actual peptide mass delivered per vial may be meaningfully lower than labeled. The FDA noted this issue specifically with compounded semaglutide products in 2024 warning letters.
- Storage and shipping degrade the peptide. Semaglutide is stable under refrigeration but degrades at higher temperatures. Products shipped without cold-chain controls may be partially degraded on arrival. Degraded peptide is not inert: oxidized or deamidated forms could have altered receptor binding and unknown immunogenicity.
- Third-party testing is rare and often non-public. A COA from the manufacturer of a research peptide is not an independent test. Independent verification by a USP-accredited lab is the only meaningful standard, and most research vendors do not provide this.
How Do You Read a GLP-1 Product Label or Prescription Information?
On a prescription label, check:
- Concentration: Ozempic pens are available at 0.25 mg/dose or 0.5 mg/dose (initial) and 1 mg/dose. Wegovy pens are 0.25 mg through 2.4 mg on an escalation schedule. Confirm the dose matches what your prescriber intended.
- Lot number and expiration: GLP-1 pens are single-patient use. Sharing pens is a needle-stick and bloodborne pathogen risk regardless of needle change.
- Storage instructions: Unused pens are refrigerated (2 to 8 degrees C). In-use Ozempic pens can be stored at room temperature for up to 56 days per the prescribing information. Heat exposure above 30 degrees C accelerates degradation.
On a COA from a compounding pharmacy or research vendor, check:
- Assay method: HPLC with UV detection or mass spectrometry is the minimum for peptide identity and purity. Ask for the chromatogram, not just the summary number.
- Endotoxin test: Must be present and must pass USP standards (below 5 EU/kg body weight per injection for parenteral products).
- Sterility test: USP Chapter 71 or equivalent. Should be listed as "passes."
- Peptide content vs. salt content: Ask specifically if the stated mg/mL accounts for acetate counterion mass.
- Who performed the testing: An internal QC test from the compounding pharmacy has different weight than a test from an independent ISO 17025-accredited laboratory.
What Are the Real Risks and Side Effects?
From the STEP 1 trial (Wilding et al., NEJM 2021, n=1,961):
| Side Effect | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Nausea | ~44% | ~16% |
| Diarrhea | ~30% | ~16% |
| Vomiting | ~24% | ~6% |
| Constipation | ~24% | ~11% |
| Discontinuation due to GI events | ~4.5% | ~0.8% |
Serious but rare risks (class-level, from prescribing information):
- Acute pancreatitis: Reported across GLP-1 agonists. A causal relationship is not firmly established; patients with prior pancreatitis should avoid this class.
- Medullary thyroid carcinoma / MEN2: Black-box warning based on rodent data. Contraindicated in patients with personal or family history of MTC or MEN2. Human epidemiological studies have not confirmed the signal but follow-up periods are limited.
- Diabetic retinopathy worsening: Seen in SUSTAIN-6 with rapid glucose lowering; relevant primarily in T2D with pre-existing retinopathy.
- Gallbladder disease: Increased cholelithiasis and cholecystitis events across trials, likely related to rapid weight loss and reduced gallbladder motility.
- Gastroparesis: Cases of delayed gastric emptying progressing to functional gastroparesis have been reported. The FDA added a label update in 2023.
- Muscle mass loss: DEXA substudies show that roughly 25 to 40 percent of weight lost on semaglutide is lean mass, consistent with other caloric restriction interventions. Resistance training and adequate protein intake are commonly recommended to mitigate this, though RCT data on this combination is limited.
FAQ
What are GLP-1 peptides?
GLP-1 peptides are 30-to-31-amino-acid incretin hormones, or synthetic analogs of them, that activate the glucagon-like peptide-1 receptor (GLP-1R). They slow gastric emptying, stimulate glucose-dependent insulin release, suppress glucagon, and reduce appetite via hypothalamic signaling. Approved analogs include semaglutide and liraglutide.
What is the difference between native GLP-1 and GLP-1 receptor agonists?
Native GLP-1 has a plasma half-life of roughly 1 to 2 minutes because DPP-4 enzyme rapidly cleaves it. Pharmaceutical GLP-1 receptor agonists are engineered with fatty-acid chains, albumin binding, or amino-acid substitutions to resist DPP-4 and extend half-life from hours (liraglutide, about 13 hours) to days (semaglutide, about 7 days).
How do GLP-1 peptides cause weight loss?
GLP-1 receptors in the hypothalamic arcuate nucleus and nucleus tractus solitarius reduce food intake by increasing satiety signals and decreasing neuropeptide Y activity. Slowed gastric emptying prolongs fullness. In STEP 1, once-weekly semaglutide 2.4 mg produced mean body-weight reduction of about 14.9 percent at 68 weeks versus 2.4 percent for placebo.
What are GLP peptides used for clinically?
FDA-approved GLP-1 receptor agonists are indicated for type 2 diabetes (liraglutide, semaglutide, dulaglutide, exenatide), chronic weight management in obesity (semaglutide 2.4 mg, liraglutide 3 mg), and cardiovascular risk reduction in adults with established cardiovascular disease (semaglutide, liraglutide per LEADER and SUSTAIN-6 trials).
How do you get GLP-1 peptides legally?
In the United States, GLP-1 receptor agonists require a prescription. Brand-name products (Ozempic, Wegovy, Victoza, Saxenda) are obtained through a licensed prescriber. FDA-registered compounding pharmacies may legally compound semaglutide or tirzepatide when a branded shortage exists, but compounded versions are not FDA-approved and carry additional quality risks.
Are research-grade GLP-1 peptides the same as pharmaceutical ones?
No. Research-chemical vendors sell peptides labeled "not for human use" that lack pharmaceutical-grade manufacturing controls (USP sterility, endotoxin testing, potency assays). Purity claims on certificates of analysis from unregulated vendors are not independently verified by the FDA and should not be trusted for human injection.
What are the most common side effects of GLP-1 peptides?
Nausea is the most common side effect, reported in roughly 44 percent of semaglutide 2.4 mg participants in STEP 1 versus about 16 percent for placebo. Vomiting, diarrhea, and constipation are also common. Rare but serious risks include pancreatitis and, based on rodent data, a theoretical thyroid C-cell tumor risk (class labeling; human relevance unproven).
How does semaglutide compare to liraglutide for weight loss?
Head-to-head, semaglutide 1 mg once weekly produced significantly greater HbA1c reduction and weight loss than liraglutide 1.2 mg once daily in the SUSTAIN 10 trial (n=577). For weight management specifically, semaglutide 2.4 mg (Wegovy) outperforms liraglutide 3 mg (Saxenda) in indirect comparisons, with roughly 15 percent versus 5 to 8 percent mean weight reduction.
What does the evidence say about GLP-1 peptides for cardiovascular outcomes?
The LEADER trial (liraglutide, n=9,340) and SUSTAIN-6 trial (semaglutide, n=3,297) both showed significant reductions in major adverse cardiovascular events in adults with type 2 diabetes and high cardiovascular risk. The SELECT trial (semaglutide 2.4 mg, n=17,604) extended this to non-diabetic obese adults, showing a 20 percent relative risk reduction in MACE.
Can oral GLP-1 peptides work the same as injectable ones?
Oral semaglutide (Rybelsus) is FDA-approved for type 2 diabetes. Bioavailability is low, roughly 1 percent, so it is co-formulated with the absorption enhancer SNAC at a 300 mg dose to deliver effective plasma levels. PIONEER trials show it is effective for glycemic control, but it has not been studied at the doses used for the weight-management indication.
What happens when you stop taking GLP-1 peptides?
Weight regain after stopping is well-documented. The STEP 4 withdrawal trial showed that participants who stopped semaglutide regained roughly two-thirds of their lost weight within one year while those who continued maintained their loss. This is consistent with GLP-1 receptors returning to baseline signaling state rather than any permanent physiological change.
Is tirzepatide a GLP-1 peptide?
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, a single peptide that activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor. SURMOUNT-1 showed mean weight reduction of about 20.9 percent at 72 weeks at the 15 mg dose, exceeding semaglutide 2.4 mg data in separate trials.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine. 2016;375(4):311-322.
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375(19):1834-1844.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232.
- Rubino DM, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021;325(14):1414-1425.
- Jastreboff AM, et al. Tirze
Related peptide guides